Open AccessSynchronous Hodgkin lymphoma and gastric adenocarcinoma
Author(s) -
Hongying Wu,
Liyan Wei,
Lumei Hao,
Xuemei Li,
Lei Wang,
Chunling Yuan
Publication year - 2018
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000009484
Subject(s) - medicine , abvd , dacarbazine , adenocarcinoma , vincristine , entecavir , capecitabine , cancer , lymphoma , oncology , gastroenterology , chemotherapy , cyclophosphamide , hepatitis b virus , colorectal cancer , immunology , virus , lamivudine
Hodgkin lymphoma (HL) is a lymphoproliferative disease arising in the lymphoid tissue, which is characterized by Reed–Sternberg cells. Adenocarcinoma is the most frequent pathological type of stomach cancer. Improved survival in HL patients leads to the development of secondary malignancies. However, synchronous occurrence of these 2 malignancies is extremely rare. Here, we present a 45-year-old male complaining of a lymph node mass in the neck, without any abdominal symptoms, diagnosed as HL and gastric adenocarcinoma with hepatitis B carrier status. We treated the patient with 8 courses of pirarubicin bleomycin, vincristine, and dacarbazine (modified ABVD), and 4 courses of capecitabine therapy concurrently along with oral entecavir, as the patient survived longer than 20 months. The prognosis of multiple primary malignancies is poor because therapy is difficult, without a standard treatment. The frequency of multiple primary malignancies is increasing in recent years, and second malignancies in patients with cancer should be taken into consideration.